aminosides

Aminoglycosides are a class of broad-spectrum antibiotics derived from streptomyces bacteria, primarily used to treat serious bacterial infections. They function by binding to the bacterial ribosome, inhibiting protein synthesis and leading to cell death. Common aminoglycosides include gentamicin, tobramycin, amikacin, and streptomycin, each with varying spectra of activity against Gram-negative bacteria, some Gram-positive bacteria, and certain intracellular pathogens.

These antibiotics are often reserved for severe infections due to their potent activity and potential for toxicity. They are frequently combined with other antibiotics, such as beta-lactams, to enhance efficacy against resistant organisms. Aminoglycosides are particularly effective against Pseudomonas aeruginosa, Enterobacteriaceae, and Mycobacterium tuberculosis, though resistance mechanisms—including enzymatic modification, reduced membrane permeability, and ribosomal mutations—have limited their usefulness over time.

Administration is typically intravenous or intramuscular, with serum levels monitored to minimize toxicity. Common side effects include nephrotoxicity and ototoxicity, which can result in permanent hearing loss or kidney damage. Due to these risks, aminoglycosides are used cautiously, especially in elderly patients or those with preexisting renal impairment. Alternative treatments are often considered when safer options are available.

Resistance to aminoglycosides has become a significant clinical challenge, driving research into new formulations and combination therapies. Their mechanism of action and broad efficacy, however, ensure they remain a critical component of antimicrobial therapy in certain infections.